Marie-Clotilde Bernard
Overview
Explore the profile of Marie-Clotilde Bernard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bernard M, Bazin E, Petiot N, Lemdani K, Commandeur S, Verdelet C, et al.
Mol Ther Nucleic Acids
. 2023 Jun;
32:794-806.
PMID: 37346973
The use of modified nucleosides is an important approach to mitigate the intrinsic immunostimulatory activity of exogenous mRNA and to increase its translation for mRNA therapeutic applications. However, for vaccine...
2.
Piras F, Plitnick L, Berglund P, Bernard M, Desert P
J Appl Toxicol
. 2022 Oct;
43(4):534-556.
PMID: 36227735
Herpes simplex virus type 2 (HSV-2) is the most common cause of genital disease worldwide. The development of an effective HSV-2 vaccine would significantly impact global health based on the...
3.
Broudic K, Amberg A, Schaefer M, Spirkl H, Bernard M, Desert P
Toxicol Appl Pharmacol
. 2022 Jul;
451:116143.
PMID: 35843341
mRNA vaccines hold tremendous potential in disease control and prevention for their flexibility with respect to production, application, and design. Recent breakthroughs in mRNA vaccination would have not been possible...
4.
Bernard M, Waldock J, Commandeur S, Strauss L, Trombetta C, Marchi S, et al.
Front Immunol
. 2022 Jul;
13:909297.
PMID: 35784305
Current vaccination strategies against influenza focus on generating an antibody response against the viral haemagglutination surface protein, however there is increasing interest in neuraminidase (NA) as a target for vaccine...
5.
Ripoll M, Bernard M, Vaure C, Bazin E, Commandeur S, Perkov V, et al.
Biomaterials
. 2022 May;
286:121570.
PMID: 35576809
The mRNA vaccine technology has promising applications to fight infectious diseases as demonstrated by the licensing of two mRNA-based vaccines, Comirnaty® (Pfizer/BioNtech) and Spikevax® (Moderna), in the context of the...
6.
Bernard M, Boudet F, Pineda-Pena A, Guinet-Morlot F
Sci Rep
. 2022 Apr;
12(1):6570.
PMID: 35449223
The World Health Organization protocol for rabies post-exposure prophylaxis (PEP) recommends extensive wound washing, immediate vaccination, and administration of rabies immunoglobulin (RIG) in severe category III exposures. Some studies have...
7.
Peubez I, Margot S, Buffin S, Pion C, Bernard M, Dinadayala P, et al.
Vaccine
. 2020 Nov;
38(50):7905-7915.
PMID: 33153770
Hemagglutinin, the major surface protein of influenza viruses, was recombinantly expressed in eukaryotic cells as a monomer instead of its native trimer, and was only immunogenic when administered with an...
8.
Lecouturier V, Bernard M, Berry C, Carayol S, Richier E, Boudet F, et al.
Vaccine
. 2019 Apr;
37(20):2679-2686.
PMID: 30967310
After decades of inconsequential infections, and sporadic outbreaks in the Asia-Pacific region between 2007 and 2013, Zika virus caused a widespread epidemic in South America in 2015 that was complicated...
9.
Giel-Moloney M, Goncalvez A, Catalan J, Lecouturier V, Girerd-Chambaz Y, Diaz F, et al.
Sci Rep
. 2018 Sep;
8(1):13206.
PMID: 30181550
Zika virus (ZIKV) is an emerging mosquito-borne pathogen representing a global health concern. It has been linked to fetal microcephaly and other birth defects and neurological disorders in adults. Sanofi...
10.
Bernard M, Barban V, Pradezynski F, De Montfort A, Ryall R, Caillet C, et al.
PLoS One
. 2015 Apr;
10(4):e0121518.
PMID: 25837802
HSV-2 vaccine is needed to prevent genital disease, latent infection, and virus transmission. A replication-deficient mutant virus (dl5-29) has demonstrated promising efficacy in animal models of genital herpes. However, the...